Viatris reported that its MR-139 ophthalmic ointment failed to meet its primary endpoint in a Phase III blepharitis trial, while advancing its MR-141 and MR-142 candidates in presbyopia and night vision impairment with positive late-stage results.
Viatris has shared an update from its Phase III clinical trial (NCT06400511) evaluating the safety and effectiveness of pimecrolimus 0.3% (MR-139) ophthalmic ointment in participants with blepharitis. The study did not meet its primary outcome measure of complete resolution of debris after six weeks of twice daily dosing.1
In a press release, Viatris Chief R&D Officer, Philippe Martin, said: "Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase III program, which may include revising the planned additional Phase III study. Thank you to the patients and investigators who contributed to the trial."
While MR-139 did not meet its primary endpoint, Viatris is focused on the development of MR-141 (phentolamine ophthalmic solution 0.75%) in treating presbyopia, and MR-142 (phentolamine ophthalmic solution 0.75%) in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.3,4
In June, the company shared positive results from the Phase III VEGA-3 trial of MR-141 (NCT06542497). The solution achieved its primary endpoint of Early Treatment Diabetic Retinopathy Study (ETDRS) (≥3-line) gain in binocular distance-corrected near visual acuity (DCNVA).
This Phase III trial is a randomized, placebo-controlled, double-blind study. It randomized 545 patients 3:2 to receive either MR-141 or placebo, once daily in the evening. Other positive outcomes from VEGA-3 demonstrated:
In a press release from the time of the announcement of these results, Martin said: "Presbyopia is a very common condition affecting approximately 90 percent of adults in the US over the age of 45, who often experience blurred near vision and eye strain. We are pleased with the positive results from the second pivotal Phase III trial, which reinforce our confidence in MR-141 and its benefit-risk profile as a potential, non-invasive option to support the millions of patients impacted by this condition."
Meanwhile, MR-142 also met its primary endpoint of ≥15-letter ETDRS (≥3-line) gain in Mesopic Low Contrast Distance Visual Acuity at day 15 in the Phase III LYNX-2 study (NCT06349759).
LYNX-2 is randomized, placebo-controlled, double-masked trial that featured a total of 199 patients randomized to receive either MR-142 or placebo, self-administered in both eyes nightly, treated, and observed over 6 weeks.
1. Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis. News release. Viatris. July 18, 2025. Accessed July 18, 2025. https://newsroom.viatris.com/2025-07-18-Viatris-Provides-Update-on-Phase-3-Study-of-MR-139-for-Blepharitis
2. A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment. ClinicalTrials.gov. Updated June 6, 2025. Accessed July 18, 2025. https://clinicaltrials.gov/study/NCT06400511
3. Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia. News release. Viatris. June 26, 2025. Accessed July 18, 2025. https://newsroom.viatris.com/2025-06-26-Viatris-Announces-Positive-Top-Line-Results-from-Second-Pivotal-Phase-3-VEGA-3-Trial-of-MR-141-in-Presbyopia
4. Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions. News release. Viatris. June 2, 2025. Accessed July 18, 2025. https://newsroom.viatris.com/2025-06-02-Viatris-Announces-Positive-Top-Line-Results-from-Phase-3-LYNX-2-Trial-of-MR-142-in-Keratorefractive-Patients-With-Visual-Disturbances-Under-Mesopic,-Low-Contrast-Conditions
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Gilead’s Yeztugo Demonstrates Strong HIV Prevention Results in Underserved Populations
July 17th 2025Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) safety and efficacy in pregnant women, young adults, and others historically excluded from HIV prevention studies.
